Skip to main content

Table 1 Medications studied by the PRCSG Pediatric Rheumatology Collaborative Study Group for Juvenile Idiopathic Arthritis and other pediatric rheumatic diseases by route(s) of administrationa

From: Pediatric Rheumatology Collaborative Study Group – over four decades of pivotal clinical drug research in pediatric rheumatology

Medications studied but without approval/licensure by regulatory agencies Medications studied with approval/licensure by regulatory agencies Studies in Progress
Oral Oral Oral
 D-penicillamine  Celecoxib  Baricitinib
 Fenoprofen  Ibuprofen  Tofacitinib
 Gold  Naproxen Subcutaneous
 Hydroxychloroquine  Rofecoxibb Certolizumab pegol
 Ketoprofen  Tolmetin Sarilumab
 Meclofenamate Oral, subcutaneous or intramuscular Secukinumab
 Oxaprozin  Methotrexate Tocilizumab
 Pirprofen Subcutaneous Intravenous
 Proquazone Adalimumab Belimumabg
Subcutaneous Canakinumabc Golimumab
Anakinra Etanercept Rituximabh
Intravenous Golimumabd  
 Intravenous immunoglobulin Subcutaneous and/or intravenous  
Infliximab Abatacepte  
Rilonacept Tocilizumabf  
  1. Biologic medications are printed in Italics
  2. bApproval withdrawn by the U.S. Food and Drug Administration due to safety concerns in adults with rheumatoid arthritis
  3. cOnly for systemic juvenile idiopathic arthritis (JIA)
  4. dApproved by European Medicines Agency only, but not by the U.S. Food and Drug Administration
  5. eBoth the intravenous and the subcutaneous form is approved for polyarticular JIA
  6. fThe intravenous forms are approved for systemic JIA and polyarticular JIA
  7. gFor systemic lupus erythematosus
  8. hFor antineutrophil cytoplasmic autoantibody (ANCA) associated vasculitis